Screener
Viking Therapeutics VKTX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Revenues | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Other income (expense): | ||
| Amortization of financing costs | — | (24) |
| Interest income, net | 5,800 | 9,864 |
| Total other income, net | 5,800 | 9,840 |
| Net loss | (158,325) | (45,629) |
| Other comprehensive loss, net of tax: | ||
| Unrealized (loss) gain on securities | (1,250) | 563 |
| Foreign currency translation gain | 16 | 9 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's other income (expense)?
- Viking Therapeutics (VKTX) reported other income (expense) of $5.8M in Q1 2026.
- How has Viking Therapeutics's other income (expense) changed year-over-year?
- Viking Therapeutics's other income (expense) decreased by 41.1% year-over-year, from $9.84M to $5.8M.
- What is the long-term trend for Viking Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Viking Therapeutics's other income (expense) has grown at a 164.2% compound annual growth rate (CAGR), from $692K to $33.7M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Viking Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude